Granules India Limited has informed the Exchange regarding a press release dated August 04, 2023, titled "Granules Pharmaceuticals, Inc. Successfully Completes USFDA Post-marketing Adverse Drug Experience (PADE) Inspection with Zero Observations".
Press Release Aug 04 2023
Filed with NSE ·
6ix hasn’t read this filing yet.
Earlier from Granules India
- Press Release Jul 14 2023
- Press Release Jun 14 2023
- Press Release Jun 13 2023
- Press Release May 19 2023
- Press Release May 16 2023
Later from Granules India
- Press Release Aug 09 2023
- Press Release Sep 30 2023
- Press Release Oct 19 2023
- Press Release Nov 09 2023
- Granules India Limited Press Release Dec 03 2023
Follow Granules India into a list and get an email when it puts out news.
Follow Granules India